May 23, 2020
Sanofi, Regeneron’s Dupixent trial meets both co-primary endpoints
Dupixent in patients 12 years and older with eosinophilic esophagitis (EoE) trial met both of its co-primary endpoints.
Pharmaceuticals, Biotechnology and Life Sciences
Tag: eosinophilic esophagitis